Rubicon Organics earnings date
Rubicon Organics (R07) Q2 2026 Earnings Report
DE:R07 Q2 2026 EPS Results
- Actual EPS
- EUR 0.01
- Consensus EPS
- EUR 0.00
- Beat/Miss
- Beat by +EUR 0.01
- One Year Ago EPS
- EUR 0.01
DE:R07 Q2 2026 Revenue Results
- Actual Revenue
- EUR 11.73M
- Expected Revenue
- EUR 10.36M
- Beat/Miss
- Beat by +EUR 1.37M
- YoY Revenue Growth
- +23.14%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/11/2026
- Time
- Before Open
- Conference Call
- Tuesday, August 11, 2026
Rubicon Organics's next earnings date is estimated for April 6, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
The call communicated clear operational momentum (record revenue, 20% yield gains at Pacifica, Cascadia brought online and certified, market share gains, and margin improvement potential excluding Cascadia start-up costs) alongside typical early-stage scaling challenges (Cascadia yields below targets, modest Q2 Cascadia revenue, higher SG&A, slight YoY decline in adjusted EBITDA, and limited cash). Management offered a coherent plan (yield optimization, in-house extraction, automation, portfolio optimization, international expansion) and expects margin and EBITDA ramp in H2 2026 into 2027. Overall, positives (revenue growth, operational wins, brand strength, certifications) materially outweigh the near-term costs and execution risks.
Management guided that Rubicon expects revenue and adjusted EBITDA to progressively ramp through Q3 and Q4 2026 (building more visibly into 2027) after a record Q2 of $18.5M (+23% YoY, +35% sequentially), noting Q2 brand mix was 1.91k 64% / Simply Bare 25% / Wildflower 6% / international 4%; international sales are expected to average ~10% of full‑year 2026 revenue (with ~1/3 of international currently in the UK). Key operational targets include sustaining ~20% higher per‑crop yields at Pacifica (H1 2026 vs H1 2025), ramping Cascadia (initial late‑Q2 revenue ~ $450k) toward planned production, converting current ~15.5k kg annual capacity across both facilities toward a pathway to ~20k kg in 18–24 months, and pushing gross margin higher (Q2 GM before fair‑value adj was 30% and would be ~36% excluding Cascadia pre‑revenue costs, with management aiming for gross margins in the 40%+ area over time). Other guidance/near‑term milestones: hydrocarbon extraction to be brought in‑house by December (benefiting vape margins in Q1 2027), continued benefit from three automated pre‑roll machines, ongoing yield and manufacturing efficiency CapEx (H1 CapEx was ~$2.6M), and an expectation that SG&A ($6.9M in Q2) will be manageable as a percent of sales while supporting growth; cash was $3.0M and working capital $20.9M at quarter‑end.
- Record Q2 Revenue and Strong Top-Line GrowthQ2 2026 net revenue of $18.5M, a record quarter representing +23% year-over-year and +35% sequential growth; management attributes growth to improved supply across the premium brand portfolio and recovery from prior distribution disruption.
- Significant Yield Improvements at PacificaPacifica delivered ~20% higher per-crop yields in H1 2026 compared to H1 2025, driven by cultivation/process improvements and genetics optimization — a key operational win underpinning volume and margin upside.
- Cascadia Operational Milestones and International ReadinessCascadia was operationalized on budget/on schedule, achieved required international certification (GACP), met premium brand quality standards, and began contributing revenue (initial Q2 contribution disclosed as ~$450k); certifications position both facilities to serve regulated international medical markets.
- Brand and Market Share Momentum1.91 thousand accounted for 64% of Q2 revenue; Simply Bare 25%, Wildflower 6%, international 4%. Rubicon achieved #1 national market share in premium flower at 10% (up nearly 2 percentage points YoY) and improved premium pre-roll share (up ~2 points YoY); 1.91 thousand won Brand of the Year awards, reinforcing consumer and trade recognition.
- Improved Gross Margin Excluding Cascadia Start-UpGross margin before fair value adjustments was 30% in Q2; management states that excluding Cascadia pre-revenue operating costs gross margin would have been ~36% (their best since Q4/2024), indicating operating leverage as volumes grow.
- Operational Productivity and Manufacturing InitiativesPre-roll automation now has three machines online (improving throughput and lowering labor cost); in-house hydrocarbon extraction project in flight (targeted to improve vape margins by Q1 2027); H1 CapEx ~ $2.6M directed at yield and manufacturing efficiency.
- Capacity and Growth PathwayCurrent annual production capacity ~15.5k kg across both facilities with a clear pathway management expects can increase output to ~20k kg over the next 18-24 months as investments mature and yields improve.
DE:R07 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Apr 06, 2027 | 2026 (Q4) | 0.01- | -0.03 | ― | ― |
| Nov 16, 2026 | 2026 (Q3) | 0.010.00 | 0.03 | -100.00% (-0.03) | |
| Aug 11, 2026 | 2026 (Q2) | -0.000.01 | 0.01 | 0.00% (+0.00) | |
| May 14, 2026 | 2026 (Q1) | 0.00-0.03 | -0.01 | -300.00% (-0.02) | |
| Mar 24, 2026 | 2025 (Q4) | 0.01-0.02 | 0 | ― | |
| Nov 12, 2025 | 2025 (Q3) | 0.000.03 | 0 | ― | |
| Aug 18, 2025 | 2025 (Q2) | 0.010.01 | -0.01 | 200.00% (+0.01) | |
| May 27, 2025 | 2025 (Q1) | ―-0.01 | -0.02 | 66.67% (+0.01) | |
| Apr 02, 2025 | 2024 (Q4) | ―-0.01 | -0.02 | 66.67% (+0.01) | |
| Nov 14, 2024 | 2024 (Q3) | ―0.00 | -0.02 | 100.00% (+0.02) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

